Recombinant Binding Protein for Multi-Toxin Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic antibodies for treating Clostridium difficile infections are costly, time-consuming to develop, have short shelf lives, and require multiple antibodies to target different pathogens, making them inefficient for widespread protection.
Innovation Solution
A recombinant binding protein with multiple disease agent-binding domains, such as those from SEQ ID NOs: 174, 164, 165, 166, and 167, is developed, which can neutralize both Clostridium difficile toxin A and B, offering a single agent that can bind to multiple targets, potentially extending shelf life and simplifying production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple therapeutic antibodies are produced to target different pathogens, then the effectiveness of treatment increases, but the complexity of production, storage, and transportation increases
Solution Approach 1:
The patent combines multiple antibody binding specificities into a single polyclonal antibody preparation. Instead of producing, storing, and transporting multiple separate monoclonal antibodies, the invention uses a single polyclonal antibody product that contains a mixture of antibodies with different binding specificities, thereby treating multiple pathogens simultaneously while simplifying the supply chain
Solution Approach 2:
The polyclonal antibody preparation serves multiple functions simultaneously - it can target different pathogens (C. difficile, C. perfringens, etc.) and different toxin types (TcdA, TcdB, CPA, CPE) with a single product, making the therapeutic agent universal rather than pathogen-specific
2Adaptability or versatility
If multiple therapeutic antibodies are developed for different targets, then the coverage of disease agents increases, but the development time and cost increase
Solution Approach 1:
The invention merges the development efforts for multiple pathogen-specific antibodies into a single polyclonal antibody development project. By immunizing an animal with a mixture of pathogen components or toxins, the immune system naturally produces a diverse repertoire of antibodies that can be harvested together as a single polyclonal preparation, dramatically reducing development time
Solution Approach 2:
The immune system of the immunized animal automatically performs the complex task of generating multiple pathogen-specific antibodies through natural immune response. The animal's immune system self-organizes to produce a diverse antibody repertoire targeting multiple antigens present in the immunogen, eliminating the need for separate hybridoma productions for each pathogen
3Quantity of substance
If large amounts of antibodies are produced for population protection, then the availability for pandemics increases, but the production cost and storage requirements increase
Solution Approach 1:
The invention consolidates the production of multiple antibody types into a single manufacturing process. Instead of running separate production lines for different monoclonal antibodies, a single polyclonal antibody preparation is produced that contains all necessary binding specificities, improving manufacturing efficiency and reducing facility requirements
Solution Approach 2:
The invention changes the fundamental parameter of antibody diversity from being achieved through multiple separate monoclonal lines to being achieved through a single polyclonal preparation. This parameter change transforms the manufacturing approach from complex multi-product production to simple single-product production with inherent diversity
4Reliability
If multiple monoclonal antibodies are used to treat different toxins, then the neutralization capability increases, but the shelf life remains short requiring frequent batch production
Solution Approach 1:
The invention combines multiple monoclonal antibody functionalities into a single polyclonal antibody product. This single product with extended shelf life replaces multiple monoclonal antibody batches, eliminating the need for frequent reproduction while maintaining comprehensive neutralization capability against multiple toxins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant binding protein effectively neutralizes Clostridium difficile toxins, providing a cost-effective and efficient treatment option with a longer shelf life, capable of targeting multiple disease agents simultaneously.
Implementation Method 1
a recombinant binding protein that neutralizes the one or more disease agents and treats the subject for exposure to the disease agent, such that the binding protein includes at least one disease agent binding domain amino acid sequence
Data Source
AI summary
Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes a disease agent that is a toxin, for example a Clostridium difficile toxin, a Shiga toxin, a ricin toxin, or an anthrax toxin.